{"entity":{"id":"mt-302","kind":"drug","name":"MT-302","aka":[],"tldr":"MT-302 programs myeloid immune cells inside the body to recognise TROP-2-bearing cancers. It is an experimental treatment in an early clinical trial.","summary":"The 2025 ASCO correlative abstract describes intravenous mRNA-LNP delivery of an anti-TROP2 scFv/truncated-CD89 CAR, functionally active upon association with FcRgamma-expressing myeloid cells. It reports tumour and blood pharmacodynamic observations, not a comparative efficacy estimate. NCT05969041 remains recruiting in its last registry update, dated January 2024; planned enrolment is 48. The registry age does not establish current local slot availability.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05969041","url":"https://clinicaltrials.gov/study/NCT05969041"},{"label":"Primary correlative abstract","url":"https://doi.org/10.1200/JCO.2025.43.16_suppl.2591"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05969041"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"In vivo myeloid cell therapy (mRNA lipid nanoparticles)","mechanism":"mRNA lipid nanoparticles encode an anti-TROP2 CAR to engage FcRgamma-expressing myeloid cells in vivo.","approvals":[],"mechanismSteps":["Intravenous lipid nanoparticles deliver messenger RNA into endogenous myeloid cells","The cells express an anti-TROP2 chimeric antigen receptor with truncated CD89","The receptor recognises TROP2-bearing tumour cells and engages FcRgamma-associated signalling","Tumour and blood pharmacodynamic findings are being studied; clinical benefit remains investigational"],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mt-302/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct05969041","kind":"trial","name":"Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","route":"/trials/nct05969041/"}]}}